Perhaps I could just add that one of the things we haven't touched on a lot this morning that I think is important in terms of the work of the committee is looking at non-prescription products and natural health products. That's a very important area that needs some research. We really don't know much about what happens there. It's the other spectrum of the seriously ill patient in hospital who's on all sorts of new drugs. The type of patient that bothers me is the consumer who might be buying products from all sorts of different places and who will mix the products.
I think one of the things we have to look at is perhaps doing more around the role of the consumer in having some awareness around risks associated with drug therapy, and really facilitate reporting and making information available. We know difficult patients who have problems with side effects and that type of thing, but I think that's an important area.